THE SHARE: Change: -0.01 SEK (-4.53%) / Price: 0.13 SEK / Feb 11, 2026, 5:29 pm (CET)
  • Home
  • About
    • Introduction
    • Board of Directors
    • Management Team
    • Medical Advisors
    • Corporate Governance
    • Career
  • Technology
    • Physiological Targeting
    • Functional Nanoparticles
    • Publications
    • Patent
  • Portfolio
    • Pipeline
    • SpagoPix
    • Tumorad
  • Investor Relations
    • The Share
    • Analyst Coverage
    • Owners
    • Financial Reports
    • Financial Calendar
    • Equity research
    • Shareholder’s Personal Data
    • Share Issue
  • Media
    • Spago Nanomedical in media
    • Press Releases
    • Subscribe
    • Presentations
    • Events
    • Image Bank
  • Contact
    • Contact us

Issuance

  • 4 Oct, 2017
    Idag inleds teckningstiden i Spago Nanomedicals företrädesemission
  • 22 Aug, 2017
    Styrelsen i Spago Nanomedical AB (publ) beslutar om företrädesemission inför kliniska studier
  • 28 Apr, 2016
    Spago Nanomedical genomför riktad emission om 15 Mkr
  • 21 Jan, 2016
    Marknadsmeddelande 20/16 – Sista dagen med handel i Spago Nanomedical BTA är den 25 januari 2016
  • 21 Jan, 2016
    Nyemissionen i Spago Nanomedical AB (publ) har registrerats
  • 10 Dec, 2015
    Företrädesemissionen i Spago Nanomedical AB (publ) övertecknades
  • 10 Nov, 2015
    Marknadsmeddelande 184/15 – Information om företrädesemission i Spago Nanomedical AB
  • 1
  • 2
  • 3
  • 4
  • Previous
Back

About Spago Nanomedical

Spago Nanomedical AB is a Swedish nanomedicines company in clinical development phase. The company´s development projects are based on a platform of polymeric materials with unique properties for more precise diagnosis and treatment of life-threatening and debilitating diseases.

Address

Spago Nanomedical AB
Scheelevägen 22
SE-223 63 Lund
Sweden

Contact

Phone: +46 46 811 88
LinkedIn

Member of:

Copyright © 2026 Spago Nanomedical AB. All Rights Reserved.
Design by Clavis Communications